US EditionPublished • loading... • Updated
Organon announces agreement to divest its JADA System for up to $465M to Laborie
Summary by ROI-NJ
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Organon announces agreement to divest its JADA System for up to $465M to Laborie
Health care company Organon said Nov. 7 that it agreed to sell its JADA system to Laborie Medical Technologies Corp., a diagnostic and therapeutic medical technology company, for $465 million. JADA is a medical device that uses a low-level intrauterine vacuum to control and treat abnormal postpartum uterine bleeding or hemorrhage. Postpartum hemorrhage is one of the most common complications of birth. In the worst cases, PPH may lead to maternal…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
